Author Affiliations: VA Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
Despite advances in the care of patients with diabetes with myocardial infarction (MI), recurrent ischemic events remain common.1 Although many explanations exist for this excess risk among patients with vs those without diabetes, one mechanism appears to be heightened platelet reactivity. It seems logical that antiplatelet therapy would be of benefit in diabetes or that more potent antiplatelet therapy would be required in diabetes.2
Deepak L. Bhatt. Antiplatelet Therapy Following Myocardial Infarction in Patients With Diabetes. JAMA. 2012;308(9):921–922. doi:10.1001/2012.jama.11467